Gregorio Cordini
Overview
Explore the profile of Gregorio Cordini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarapura Martinez V, Buonincontro B, Cassarino C, Bernatowiez J, Colado A, Cordini G, et al.
Front Oncol
. 2023 Apr;
13:1143881.
PMID: 37020867
The treatment of chronic lymphocytic leukemia (CLL) patients with venetoclax-based regimens has demonstrated efficacy and a safety profile, but the emergence of resistant cells and disease progression is a current...
2.
Santarelli I, Ibaceta Alaniz E, Cabo C, Guarino B, Cordini G, Fernandez S, et al.
Medicina (B Aires)
. 2021 Dec;
81(6):1052-1055.
PMID: 34875606
Obinutuzumab is a fully humanized monoclonal antibody against CD20 used in the treatment of chronic lymphocytic leukemia. Fatal cardiovascular events have been described, but only in patients with known cardiovascular...
3.
Elias E, Sarapura Martinez V, Amondarain M, Colado A, Cordini G, Bezares R, et al.
Cancer Immunol Immunother
. 2021 Sep;
71(4):979-987.
PMID: 34467417
Venetoclax treatment has demonstrated efficacy and a safety profile in chronic lymphocytic leukemia (CLL) patients, however the emergence of resistant cells is a current complication. We and others, previously reported...
4.
Vereertbrugghen A, Colado A, Gargiulo E, Bezares R, Fernandez Grecco H, Cordini G, et al.
Front Oncol
. 2021 Aug;
11:598319.
PMID: 34381700
Current standard treatment of patients with hairy cell leukemia (HCL), a chronic B-cell neoplasia of low incidence that affects the elderly, is based on the administration of purine analogs such...
5.
Colado A, Elias E, Sarapura Martinez V, Cordini G, Morande P, Bezares F, et al.
Sci Rep
. 2021 Jun;
11(1):12926.
PMID: 34155276
Hypogammaglobulinemia is the most frequently observed immune defect in chronic lymphocytic leukemia (CLL). Although CLL patients usually have low serum levels of all isotypes (IgG, IgM and IgA), standard immunoglobulin...
6.
Risnik D, Elias E, Keitelman I, Colado A, Podaza E, Cordini G, et al.
Leuk Lymphoma
. 2020 Apr;
61(10):2409-2418.
PMID: 32306816
Ibrutinib is a BTK/ITK inhibitor with efficacy for the treatment of various lymphoid cancers, including CLL. Considering that innate and adaptative immune defects are a dominant feature of CLL patients,...
7.
Colado A, Marin Franco J, Elias E, Amondarain M, Vergara Rubio M, Martinez V, et al.
Am J Hematol
. 2020 Apr;
95(7):E174-E178.
PMID: 32267009
No abstract available.
8.
Elias E, Almejun M, Colado A, Cordini G, Vergara-Rubio M, Podaza E, et al.
Haematologica
. 2018 May;
103(10):e458-e461.
PMID: 29748439
No abstract available.
9.
Pisarevsky A, Plumet Garrido J, Mariash N, Cordini G, Tiraboschi N, Petrucci E
Medicina (B Aires)
. 2011 Sep;
71(4):377.
PMID: 21893454
No abstract available.